Panacea Index Logo

Command Palette

Search for a command to run...

Melatonin, autophagy and intestinal bowel disease.

Current pharmaceutical design
January 1, 2014
Elena Talero et al. (3 authors)
Journal ArticleResearch Support, Non-U.S. Gov'tReviewHuman Study
Study Details

Study Goal

The researchers aimed to review melatonin's immunoregulatory and anti-inflammatory effects in inflammatory bowel disease (IBD), focusing on its mechanisms and potential therapeutic benefits.

Results Summary

Melatonin demonstrated anti-inflammatory and immunomodulatory effects in colitis models, including reducing T cells, modulating macrophage activity, and suppressing proinflammatory cytokines. However, human studies are limited and report mixed effects, possibly due to melatonin's dual role in autophagy regulation.

Population

Experimental models of colitis and limited human studies (case reports and clinical trials).

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (18)
InterventionDirectionEndpointPopulationDosageImpactClaim #
melatonin
decrease
colitis
experimental models
-
exerts important inmunoregulatory and antiinflammatory effects
#1
melatonin
decrease
T cells number
experimental models of colitis
-
reduction
#2
melatonin
neutral
macrophage activity
experimental models of colitis
-
modulation
#3
melatonin
decrease
NFκB activity
experimental models of colitis
-
suppression
#4
melatonin
decrease
cell adhesion molecules
experimental models of colitis
-
inhibition
#5
melatonin
decrease
proinflammatory cytokines
experimental models of colitis
-
inhibition
#6
melatonin
decrease
COX-2 levels
experimental models of colitis
-
suppression
#7
melatonin
decrease
iNOS levels
experimental models of colitis
-
suppression
#8
melatonin
decrease
synthesis of PGE2
experimental models of colitis
-
suppression
#9
melatonin
decrease
synthesis of NO
experimental models of colitis
-
suppression
#10
melatonin
decrease
matrix metalloproteinase (MMP) -2 activity
experimental models of colitis
-
reduction
#11
melatonin
decrease
matrix metalloproteinase (MMP) -9 activity
experimental models of colitis
-
reduction
#12
melatonin
neutral
apoptosis
experimental models of colitis
-
modulation
#13
melatonin
decrease
free radicals
IBD
-
scavenger effect
#14
melatonin
increase
several antioxidant enzymes
IBD
-
activation
#15
melatonin
neutral
IBD
human studies
-
possible beneficial effects
#16
melatonin
neutral
IBD
human studies
-
possible harmful effects
#17
melatonin
neutral
autophagy
IBD
-
duality of its effects
#18
Abstract

The intestinal epithelium forms a barrier against the intestinal contents and the wider environment, allowing entry of selected molecules for nutrition and programming of the mucosal immune system, but excluding toxins and most microorganisms. Many receptors and signalling pathways are coupled and implicated in the epithelial control and significant advances have been achieved in the understanding of the pathogenesis of inflammatory bowel disease (IBD) and in the introduction of biologics. However, not all of the patients respond and many lose their response. Data from experimental studies have documented that the pineal secretory product melatonin exerts important inmunoregulatory and antiinflammatory effects in different models of colitis. These actions have been associated to a variety of mechanisms, such as reduction of T cells number, modulation of macrophage activity, suppression of NFκB activity, inhibition of cell adhesion molecules and proinflammatory cytokines , suppression of COX-2 and iNOS levels and the consequent synthesis of PGE2 and NO, reduction of matrix metalloproteinase (MMP) -2 and -9 activity, and modulation of apoptosis. In addition, the beneficial effects of melatonin in IBD are related to its scavenger effect on free radicals and the activation of several antioxidant enzymes. However, only a small number of human studies report possible beneficial and also possible harmful effects of melatonin in case reports and clinical trials. There is a considerable bulk of information supporting the connection between autophagy and human diseases, including IBD, and although autophagy is actually considered more a pro-survival than a pro-death pathway, these two features of its action are relevant in human diseases, having therapeutic potential for both activators and inhibitors of autophagy. Some of the opposite effects than have been reported for melatonin in IBD could be related to the duality of its effects on autophagy, which itself can be beneficial or detrimental. In this review, new data for melatonin in IBD are discussed, trying to provide recent information of different molecular mechanism including the role of the autophagy regulation.

Medical Subject Headings (MeSH)
AutophagyHumansImmunity, InnateInflammatory Bowel DiseasesMelatonin
Study Links
Quality Scores
Safety65
Efficacy75/10
Quality70/10
Citation Metrics
Total Citations15
Citations/Year1.4
Relative Citation Ratio0.54
NIH Percentile29.1%
Research Impact Scores
APT Score0.05
Weight Score0.74
Normalized Score0.70
Related Supplements
Melatonin, autophagy and intestinal bowel disease. | Panacea Index